In addition, we screened four potential small-molecule compounds for GC, including AZD6482 (PI3K inhibitor), BX.795 (TBK1 inhibitor), GDC0941 (dual PI3K and mTOR inhibitor), and pazopanib (tyrosine kinase inhibitor). Here, TBK1 is linked to gastric cancer.